Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Share:
Related AGN
Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
Pfizer Has Had A Busy M&A Year...Or Has It?
Candidate Clinton's harsh comments on high price of Mylan's EpiPen sends biotechs reeling; IBB down 2% (Seeking Alpha)
Related VRX
Valeant's Management Continues To Take The Right Steps
Drug Price Hike Concerns Spill Over Into Other Pharma Stocks
Healthcare Drug Pricing a Factor for the Market on Wednesday (GuruFocus)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!